Alam Kamran 4

What Happened

Alam Kamran, CFO of Taysha Gene Therapies (TSHA), reported two open-market sales to cover tax withholding on vested restricted stock units. On 2026-01-23 he disposed of 78,968 shares at a weighted average price of $4.75 for proceeds of $375,098. On 2026-01-26 he disposed of 23,849 shares at a weighted average price of $4.61 for proceeds of $109,944. Total proceeds across both transactions were about $485,042. These were sales (routine sell-to-cover for tax obligations), not purchases.

Key Details

• Transaction dates: 2026-01-23 (78,968 shares) and 2026-01-26 (23,849 shares).
• Reported weighted-average prices and ranges:
  • 78,968 shares at $4.75 (prices ranged $4.635–$4.99 per footnote).
  • 23,849 shares at $4.61 (prices ranged $4.505–$4.715 per footnote).
• Purpose: Mandatory sell-to-cover to satisfy income tax liabilities on RSU vesting (footnote F1).
• Filing: Form 4 filed 2026-01-27 (timely relative to the reported transaction dates).
• Shares owned after the transactions: not disclosed in the provided filing.

Context

• These transactions are tax-withholding sales tied to RSU vesting (routine administrative transactions) and do not necessarily indicate a change in insider sentiment.
• Footnotes note weighted-average pricing and offer to provide per-trade price details on request (useful if you want exact price-by-trade breakdown).